Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with normal hepatic function or hepatic impairment (mild, moderate or severe)~* Body mass index (BMI) 18.5-40.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods~* History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease~* Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)~* Any donation of blood or plasma in excess of 400 mL within the 3 months preceding screening~* History of significant drug abuse, or a positive drug test at the screening visit (Visit 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with hepatic impairment (Type: EXPERIMENTAL): None
- Subjects with normal hepatic function (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).